Towards a cure for HIV-are we making progress?

The Lancet

Volumn 384, Issue 9939, 2014, Pages 209-211

  Lewin, Sharon R ^a,b   Deeks, Steven G ^c   Barré Sinoussi, Françoise ^d  

^a MONASH UNIVERSITY   (Australia)

^b BURNET INSTITUTE   (Australia)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BMS 936559; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PROGRAMMED DEATH 1 LIGAND 1; ROMIDEPSIN; VORINOSTAT;

CD4+ T LYMPHOCYTE; CYTOMEGALOVIRUS; DISEASE DURATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFECTION CONTROL; LIFE EXPECTANCY; NONHUMAN; NOTE; PREVENTION STUDY; PRIORITY JOURNAL; TREATMENT PLANNING; VIRUS INFECTIVITY; ANTIVIRAL THERAPY; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL (TOPIC); GENE THERAPY; GRAFT VERSUS HOST REACTION; REMISSION; STEM CELL TRANSPLANTATION; UNITED STATES; VIRUS TRANSMISSION;

ANTI-RETROVIRAL AGENTS; BIOLOGICAL MARKERS; HIV INFECTIONS; HUMANS; REMISSION INDUCTION; T-LYMPHOCYTES; TIME FACTORS;

EID: 84904439274     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)61181-8     Document Type: Note

References (15)

1. Maartens G, Celum C, Lewin SR. HIV infection: epidemiology, pathogenesis, treatment, and prevention. Lancet 2014; published online June 5. http://dx.doi.org/10.1016/S0140-6736(14)60164-1.
2. Saez-Cirion A, Bacchus C, Hocqueloux L, et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog 2013; 9: e1003211.
3. Persaud D, Gay H, Ziemniak C, et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med 2013; 369: 1828-35.
4. National Institute of Allergy and Infectious Diseases. "Mississippi baby" now has detectable HIV, researchers find. NIH News July 10, 2014. http://www. niaid.nih.gov/news/newsreleases/2014/Pages/MississippiBabyHIV.aspx (accessed July 14, 2014).
5. Henrich TJ, Hu Z, Li JZ, et al. Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. J Infect Dis 2013; 207: 1694-702.
6. Henrich TJ, Hanhauser E, Sirignano MN, et al. HIV-1 rebound following allogeneic stem cell transplantation and treatment interruption. Conference on Retroviruses and Opportunistic Infections (CROI 2014); Boston, MA, USA; March 3-6, 2014. 144LB.
7. Archin NM, Liberty AL, Kashuba AD, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 2012; 487: 482-85.
8. Bullen CK, Laird GM, Durand CM, Siliciano JD, Siliciano RF. New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat Med 2014; 20: 425-29.
9. Shan L, Deng K, Shroff NS, et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 2012; 36: 491-501.
10. Spina CA, Anderson J, Archin NM, et al. An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients. PLoS Pathog 2013; 9: e1003834.
11. Søgaard OS, Graversen ME, Leth S, et al. The HDAC inhibitor romidepsin is safe and effectively reverses HIV-1 latency in vivo as measured by standard clinical assays. 20th International AIDS Conference; Melbourne, Australia; July 20-25, 2014. TUAA0106LB.
12. Hansen SG, Piatak M, Jr, Ventura AB, et al. Immune clearance of highly pathogenic SIV infection. Nature 2013; 502: 100-04.
13. Barouch DH, Whitney JB, Moldt B, et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 2013; 503: 224-28.
14. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366: 2455-65.
15. Tebas P, Stein D, Tang WW, et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med 2014; 370: 901-10.